PMC:7293470 / 3365-3545 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T115","span":{"begin":95,"end":99},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T116","span":{"begin":173,"end":177},"obj":"PR:000001822"},{"id":"T51111","span":{"begin":95,"end":99},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T81051","span":{"begin":173,"end":177},"obj":"PR:000001822"}],"text":"ined or designed for bifunctional activity.\nWe are developing a second generation bifunctional drug called DRhQ that can simultaneously bind to and inhibit both the TCR and CD74 th"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T57","span":{"begin":34,"end":42},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T58","span":{"begin":62,"end":63},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ined or designed for bifunctional activity.\nWe are developing a second generation bifunctional drug called DRhQ that can simultaneously bind to and inhibit both the TCR and CD74 th"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T61","span":{"begin":95,"end":99},"obj":"Chemical"}],"attributes":[{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"ined or designed for bifunctional activity.\nWe are developing a second generation bifunctional drug called DRhQ that can simultaneously bind to and inhibit both the TCR and CD74 th"}

{"project":"LitCovid-PubTator","denotations":[{"id":"214","span":{"begin":107,"end":111},"obj":"Chemical"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ined or designed for bifunctional activity.\nWe are developing a second generation bifunctional drug called DRhQ that can simultaneously bind to and inhibit both the TCR and CD74 th"}